BDMD

Baird Medical Investment Holdings Limited
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$2.83M
P/E Ratio
—
EPS
$-0.55
Beta
-0.99
52W High
$3.70
52W Low
$0.07
50-Day MA
$0.73
200-Day MA
$1.31
Dividend Yield
—
Profit Margin
-65.10%
Forward P/E
1.13
PEG Ratio
—

About Baird Medical Investment Holdings Limited

Baird Medical Investment Holdings Limited, along with its subsidiaries manufactures microwave ablation and other medical devices for minimally invasive tumor treatment. The company is headquartered in Guangzhou, China.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$24.49M
Gross Profit (TTM)$20.97M
EBITDA$-13.33M
Operating Margin8.54%
Return on Equity-46.00%
Return on Assets-11.90%
Revenue/Share (TTM)$0.81
Book Value$1.09
Price-to-Book0.14
Price-to-Sales (TTM)0.12
EV/Revenue0.972
EV/EBITDA5.91
Quarterly Earnings Growth (YoY)-0.30%
Quarterly Revenue Growth (YoY)24.60%
Shares Outstanding$32.11M
Float$6.50M
% Insiders86.31%
% Institutions0.99%

Historical Volatility

HV 10-Day
181.55%
HV 20-Day
136.04%
HV 30-Day
126.36%
HV 60-Day
101.89%
HV Rank
—

Volatility is currently expanding

Analyst Ratings

Consensus ($4.00 target)

Latest News

Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced that its strategic partner, Tianjin Yuanshan Medical Technology Co., Ltd. (“Alpmed”), has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) and an application for CE conformity assessment in the European Union for an irreversible electroporation (IRE) system.

GlobeNewsWire11/5/2026Neutral
Baird Medical Issues Statement Regarding Recent Share Price Volatility

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has provided the following statement regarding recent volatility in the market price of its ordinary shares. The Company is closely monitoring these fluctuations in the market price of its ordinary shares and the associated trading activity, and is not currently aware of any material development or otherwise undisclosed reason that would explain the recent decline in its ordinary share price.

GlobeNewsWire11/4/2026Neutral
Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company's shares, and Baird Medical's shares will continue to trade, uninterrupted, on the Nasdaq Capital Market under the ticker “BDMD.

GlobeNewsWire11/4/2026Neutral
Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China

China Resources Medical Devices to serve as exclusive distributor for Baird's microwave ablation (MWA) products in 19 markets in the PRC Agreement includes initial purchase order of RMB 6 million ($900,000) NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced that its PRC subsidiary, Nanjing Changcheng Medical Equipment Company Limited, has entered into a distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. (“China Resources Medical Devices”), a subsidiary of China Resources Pharmaceutical Group Limited (Stock Code: 03320.HK).

GlobeNewsWire11/2/2026Neutral
Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (NASDAQ: BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership.

GlobeNewsWire10/5/2026Neutral
Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C.

GlobeNewsWire9/15/2026Neutral
Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”), further supporting the Company's commercial activities in the country.

GlobeNewsWire8/20/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDMD and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/7/2026